Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial

Schizophrenia Research

Volumn 118, Issue 1-3, 2010, Pages 218-223

  Narula, Preeta Kaur ^a   Rehan, H S ^a   Unni, K E S ^a   Gupta, Neeraj ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Leptin; Metabolic syndrome; Olanzapine; Schizophrenia; Topiramate; Weight

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PLACEBO; TOPIRAMATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTICHOLINERGIC SYNDROME; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BODY MASS; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTRIGLYCERIDEMIA; INCREASED APPETITE; INDIAN; INSOMNIA; INSULIN RESISTANCE; LEPTIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; PARALLEL DESIGN; PARESTHESIA; PATIENT MONITORING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNDERWEIGHT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; INSULIN; LIPIDS; MALE; METABOLIC DISEASES; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; SCHIZOPHRENIA; WEIGHT GAIN; YOUNG ADULT;

EID: 77951975951     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.001     Document Type: Article

References (43)

1. Afshar H., Roohafza H., Mousavi G., Golchin S., Toghianifar N., Sadeghi M., Talaei M. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol. 2009, 23:157-162.
2. Astrup A., Caterson I., Zelissen P., Guy-Grand B., Carruba M., Levy B., Sun X., Fitchet M. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 2004, 12:1658-1669.
3. Atmaca M., Kuloglu M., Tezcan E., Gecici O., Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr. Res. 2003, 60:99-100.
4. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing acute weight changes in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J. Clin. Psychiatry 2001, 62:231-238.
5. Ben-Menachem E., Axelsen M., Johanson E.H., Stagge A., Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res. 2003, 11:556-562.
6. Bray G.A., Hollander P., Klein S., Kushner R., Levy B., Fitchet M., Perry B.H. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 2003, 11:722-733.
7. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 2001, 24:43-49.
8. Drapalski A.L., Rosse R.B., Peebles R.R., Schwartz B.L., Marvel C.L., Deutsch S.I. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin. Neuropharmacol. 2001, 24:290-294.
9. Graham K.A., Perkins D.O., Edwards L.J., Barrier R.C., Lieberman J.A., Harp J.B. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychiatry 2005, 162:118-123.
10. Hester E.K., Thrower M.R. Current options in the management of olanzapine-associated weight gain. Ann. Pharmacother. 2005, 39:302-310.
11. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., Kanai A., Kase A., Uchikado H., Hirayasu Y. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J. Psychopharmacol. 2006, 20:75-79.
12. Jayaram M.B., Hosalli P., Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2006, 2:CD005237.
13. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
14. Kim J.H., Yim S.J., Nam J.H. A 12-week randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr. Res. 2006, 82:115-117.
15. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D. Long term olanzapine treatment: weight change and weight related health factors in schizophrenia. J. Clin. Psychiatry 2001, 62:92-100.
16. Klein K.M., Theisen F., Knake S., Oertel W.H., Hebebrand J., Rosenow F., Hamer H.M. Topiramate, nutrition and weight change: a prospective study. J. Neurol. Neurosurg. Psychiatry 2008, 79:590-593.
17. Ko Y.H., Joe S.H., Jung I.K., Kim S.H. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol. 2005, 28:169-175.
18. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kuhn M., Uhr M., Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry 1999, 156:312-314.
19. Landmark C.J. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
20. Lee C., Wu K.H., Habil H., Dyachkova Y., Lee P. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust. N. Z. J. Psychiatry 2006, 40:437-445.
21. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Lobos C.A., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166:152-163.
22. Lévy E., Agbokou C., Ferreri F., Chouinard G., Margolese H.C. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can. J. Clin. Pharmacol. 2007, 14:234-239.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J.B., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
24. Lin Y.H., Liu C.Y., Hsiao M.C. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin. Neurosci. 2005, 59:613-615.
25. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 2003, 160:290-296.
26. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Melkersson K.I., Hulting A., Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry 2000, 61:742-749.
28. Mousavi S.Gh., Golchin Sh., Afshar H., Afza H.R.R. Add on topiramate for the pharmacological management of schizophrenia: a double blind randomized clinical trial. Iranian J. Psych. Behav. Sci. 2007, 1:16-22.
29. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(suppl 1):1-93.
30. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry 1991, 36:239-245.
31. Picard F., Deshaies Y., Lalonde J., Samson P., Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 2000, 8:656-663.
32. Richard D., Ferland J., Lalonde J., Samson P., Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000, 16:961-966.
33. Richard D., Picard F., Lemieux C., Lalonde J., Samson P., Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. Relat. Metab. Disord. 2002, 26:344-353.
34. Schneiderhan M.E., Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?. Am. J. Ther. 2007, 14:581-584.
35. Smith U., Axelsen M., Hellebo-Johanson E., Lundgren B., Ben-Menachen E. Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity. Obes. Res. 2000, 8(1S):105.
36. Supuran C.T., Di Fiore A., De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin. Emerg. Drugs 2008, 13:383-392.
37. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, 1994. World Health Organization, Geneva.
38. Tiihonen J., Halonen P., Wahlbeck K., Repo-Tiihonen E., Hyvärinen S., Eronen M., Putkonen H., Takala P., Mehtonen O.P., Puck M., Oksanen J., Koskelainen P., Joffe G., Aer J., Hallikainen T., Ryynänen O.P., Tupala E. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychiatry 2005, 66:1012-1015.
39. Tremblay A., Chaput J.P., Bérubé-Parent S., Prud'homme D., Leblanc C., Alméras N., Després J.P. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur. J. Clin. Pharmacol. 2007, 63:123-134.
40. WHO Technical Report Series 854 Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee 1995, World Health Organization, Geneva.
41. WHO Technical Report Series 894 Obesity: preventing and managing the global epidemic. Report of a WHO Consultation 2000, World Health Organization, Geneva.
42. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163. WHO expert consultation.
43. York D.A., Singer L., Thomas S., Bray G.A. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000, 16:967-975.